Jmac Enterprises LLC Sells 1,038 Shares of Pfizer Inc. (NYSE:PFE)

Jmac Enterprises LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 47,466 shares of the biopharmaceutical company’s stock after selling 1,038 shares during the quarter. Jmac Enterprises LLC’s holdings in Pfizer were worth $1,374,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Massachusetts Financial Services Co. MA boosted its stake in shares of Pfizer by 3.2% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 71,794,056 shares of the biopharmaceutical company’s stock valued at $2,008,798,000 after purchasing an additional 2,241,609 shares in the last quarter. Van ECK Associates Corp boosted its position in Pfizer by 2.8% in the third quarter. Van ECK Associates Corp now owns 16,560,256 shares of the biopharmaceutical company’s stock valued at $477,929,000 after buying an additional 456,168 shares in the last quarter. Federated Hermes Inc. grew its stake in shares of Pfizer by 3.3% during the second quarter. Federated Hermes Inc. now owns 14,923,545 shares of the biopharmaceutical company’s stock worth $417,561,000 after buying an additional 470,003 shares during the last quarter. National Pension Service increased its holdings in shares of Pfizer by 18.1% during the third quarter. National Pension Service now owns 11,516,769 shares of the biopharmaceutical company’s stock worth $333,295,000 after buying an additional 1,762,520 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its stake in shares of Pfizer by 2.4% in the 2nd quarter. Envestnet Asset Management Inc. now owns 10,260,067 shares of the biopharmaceutical company’s stock valued at $287,077,000 after acquiring an additional 238,850 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of Pfizer stock opened at $27.43 on Thursday. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $31.54. The firm has a market capitalization of $155.44 billion, a P/E ratio of 36.96, a price-to-earnings-growth ratio of 0.88 and a beta of 0.67. The business’s fifty day simple moving average is $28.96 and its 200 day simple moving average is $28.64. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.40%. The firm’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.17) earnings per share. As a group, analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.12%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is currently 227.03%.

Insider Buying and Selling at Pfizer

In other news, Director Scott Gottlieb acquired 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at $282,400. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on PFE shares. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Citigroup assumed coverage on shares of Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective on the stock. UBS Group upped their price target on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Finally, Sanford C. Bernstein started coverage on Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective on the stock. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.